Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AVGR 
Avinger Inc (AVGR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/31/2025: AVGR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -53.15% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.52M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1703421 | Beta 1.09 | 52 Weeks Range 0.36 - 4.37 | Updated Date 04/2/2025 |
52 Weeks Range 0.36 - 4.37 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.76 |
Earnings Date
Report Date 2025-03-18 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin -256.25% | Operating Margin (TTM) -222.36% |
Management Effectiveness
Return on Assets (TTM) -69.57% | Return on Equity (TTM) -1476.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1209364 | Price to Sales(TTM) 0.21 |
Enterprise Value 1209364 | Price to Sales(TTM) 0.21 | ||
Enterprise Value to Revenue 0.17 | Enterprise Value to EBITDA -0.4 | Shares Outstanding 3196970 | Shares Floating 2655351 |
Shares Outstanding 3196970 | Shares Floating 2655351 | ||
Percent Insiders 7.94 | Percent Institutions 10.16 |
Analyst Ratings
Rating 4 | Target Price 5 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Avinger Inc
Company Overview
History and Background
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures, and sells image-guided, catheter-based systems used to treat peripheral artery disease (PAD). Founded in 2007, it has focused on developing technologies for real-time intravascular imaging during minimally invasive procedures.
Core Business Areas
- Image-Guided Catheters: Avinger's primary business is the development and sale of Lumivascular technology, which includes catheters that provide real-time intravascular imaging during atherectomy procedures for PAD.
Leadership and Structure
The leadership team consists of experienced executives in the medical device industry. Avinger operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- Pantheris Next Gen: An image-guided atherectomy system used to treat PAD. Market share data for specific products is difficult to obtain due to the fragmented nature of the atherectomy market and Avinger's relatively small size. Competitors include Medtronic (MDT), Boston Scientific (BSX) and Philips (PHG).
- Ocelot: An image-guided catheter for crossing chronic total occlusions (CTOs) in peripheral arteries. Competitors include Medtronic (MDT), Boston Scientific (BSX) and Philips (PHG).
Market Dynamics
Industry Overview
The peripheral artery disease (PAD) treatment market is driven by an aging population, increasing prevalence of diabetes and obesity, and technological advancements in minimally invasive procedures.
Positioning
Avinger focuses on the niche market of image-guided atherectomy. Its advantage lies in its Lumivascular technology which allows real-time visualization. They have a limited share of the overall PAD market.
Total Addressable Market (TAM)
The global peripheral vascular devices market is estimated to be in the billions of dollars. Avinger is attempting to capture a portion of this TAM through its Lumivascular technology, estimated 15-25 billion, their current market share would indicate a small proportion relative to the TAM.
Upturn SWOT Analysis
Strengths
- Proprietary Lumivascular technology
- Real-time intravascular imaging
- Focus on minimally invasive procedures
Weaknesses
- Limited market share
- Financial instability
- Dependence on specific technology
Opportunities
- Expanding indications for Lumivascular technology
- Strategic partnerships and collaborations
- Growth in emerging markets
Threats
- Intense competition from larger medical device companies
- Reimbursement challenges
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- MDT
- BSX
- PHG
Competitive Landscape
Avinger's Lumivascular technology offers a unique advantage in terms of real-time visualization, but its size and resources are significantly smaller compared to its competitors. This makes it difficult to compete on price or market reach.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Avinger's historical growth has been inconsistent, with periods of rapid growth followed by declines.
Future Projections: Analyst projections depend on the company's ability to improve its financial stability, and market expansion.
Recent Initiatives: Recent initiatives may involve new product launches, strategic partnerships, or cost-cutting measures. Data required for analysis.
Summary
Avinger possesses unique Lumivascular technology providing real-time visualization in PAD treatment, a notable strength. However, the company faces challenges due to its small size, intense competition, and financial constraints. To succeed, Avinger must improve its market penetration and address its financial stability for market share expansion. Strategic partnerships and expanding into new market segments are crucial for long-term growth and sustainability.
Similar Companies
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
MDT
Medtronic PLC
MDT
Medtronic PLC
PHG
Koninklijke Philips NV ADR
PHG
Koninklijke Philips NV ADR
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q)
- Industry reports
- Press releases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share data is estimated due to limited availability. The situation of Avinger Inc. is very dynamic.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avinger Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2015-01-30 | CEO - | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 68 | Website https://avinger.com |
Full time employees 68 | Website https://avinger.com | ||
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.